X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (382) 382
humans (334) 334
oncology (305) 305
colorectal cancer (265) 265
anti-egfr therapy (207) 207
cetuximab (200) 200
cancer (162) 162
chemotherapy (143) 143
mutation (127) 127
anti-egfr (121) 121
female (121) 121
colorectal neoplasms - drug therapy (118) 118
colorectal neoplasms - genetics (118) 118
panitumumab (116) 116
receptor, epidermal growth factor - antagonists & inhibitors (111) 111
metastasis (108) 108
care and treatment (101) 101
colorectal neoplasms - pathology (100) 100
growth-factor receptor (99) 99
kras (99) 99
1st-line treatment (97) 97
antineoplastic agents - therapeutic use (97) 97
male (96) 96
animals (83) 83
acquired-resistance (82) 82
middle aged (81) 81
tumors (81) 81
aged (79) 79
epidermal growth factor (79) 79
antibodies, monoclonal - therapeutic use (75) 75
monoclonal antibodies (72) 72
adult (61) 61
anti-egfr antibody (60) 60
genetic aspects (60) 60
prognosis (60) 60
analysis (58) 58
egfr (58) 58
cell line, tumor (56) 56
pharmacology & pharmacy (56) 56
therapy (56) 56
metastatic colorectal cancer (55) 55
braf (53) 53
research (53) 53
antineoplastic combined chemotherapy protocols - therapeutic use (52) 52
neoplasm metastasis (52) 52
cancer therapies (51) 51
health aspects (51) 51
cell lung-cancer (50) 50
open-label (50) 50
cetuximab plus irinotecan (49) 49
colorectal carcinoma (49) 49
metastatic colorectal-cancer (49) 49
ras proteins - genetics (47) 47
bevacizumab (46) 46
colorectal-cancer (46) 46
ras mutations (46) 46
receptor, epidermal growth factor - immunology (46) 46
targeted therapy (45) 45
medicine & public health (43) 43
receptor, epidermal growth factor - metabolism (43) 43
treatment outcome (43) 43
colon-cancer (42) 42
proto-oncogene proteins b-raf - genetics (42) 42
aged, 80 and over (41) 41
epidermal growth factor receptors (41) 41
hematology, oncology and palliative medicine (41) 41
molecular targeted therapy (41) 41
phase-iii trial (41) 41
resistance (41) 41
proto-oncogene proteins p21 - genetics (40) 40
digestive system diseases (39) 39
drug therapy (39) 39
expression (39) 39
metastases (39) 39
mice (39) 39
monoclonal-antibody (39) 39
patients (39) 39
cell biology (38) 38
survival (38) 38
antibodies, monoclonal, humanized (37) 37
fluorouracil (37) 37
kinases (37) 37
antineoplastic agents - pharmacology (36) 36
biomarkers (36) 36
lung-cancer (36) 36
antibodies, monoclonal - administration & dosage (35) 35
development and progression (35) 35
kras mutations (35) 35
mutations (35) 35
pathology (35) 35
proto-oncogene proteins - genetics (35) 35
antibodies (34) 34
biomarkers, tumor - genetics (34) 34
proto-oncogene proteins p21 (33) 33
medicine (32) 32
disease-free survival (31) 31
gene mutations (31) 31
studies (31) 31
antibodies, monoclonal - pharmacology (30) 30
neoplasms (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (546) 546
French (28) 28
German (8) 8
Spanish (5) 5
Russian (3) 3
Czech (2) 2
Japanese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Oncology, ISSN 1574-7891, 02/2017, Volume 11, Issue 2, pp. 208 - 219
Journal Article
Annals of oncology, ISSN 0923-7534, 2016, Volume 27, Issue 8, pp. 1386 - 1422
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2008, Volume 14, Issue 20, pp. 6456 - 6468
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel... 
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | TARGETED THERAPY | KRAS MUTATIONS | GROWTH-FACTOR RECEPTOR | NUDE-MICE | TUMOR XENOGRAFTS | GEFITINIB | ONCOLOGY | GENE-EXPRESSION | TYROSINE KINASE INHIBITOR | EGFR MUTATIONS | ANTITUMOR-ACTIVITY | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology | Index Medicus
Journal Article
CANCER TREATMENT REVIEWS, ISSN 0305-7372, 07/2014, Volume 40, Issue 6, pp. 701 - 715
Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line... 
3RD-LINE CHEMOTHERAPY | Targeted therapy | MITOMYCIN-C | Colorectal cancer | ANTI-EGFR THERAPY | Salvage therapy | Refractory | LIVER METASTASES | K-RAS MUTATIONS | Chemotherapy | PHASE-II TRIAL | HEPATIC ARTERIAL INFUSION | ONCOLOGY | EVERY 2 WEEKS | COMBINATION CHEMOTHERAPY | GROWTH-FACTOR
Journal Article
Cancer Discovery, ISSN 2159-8274, 2013, Volume 3, Issue 6, pp. 658 - 673
Journal Article
Molecular Carcinogenesis, ISSN 0899-1987, 01/2017, Volume 56, Issue 1, pp. 106 - 117
Journal Article
Annals of Oncology, ISSN 0923-7534, 2015, Volume 26, Issue 8, pp. 1710 - 1714
Journal Article
Advances in experimental medicine and biology, ISSN 0065-2598, 2018, Volume 1110, pp. 133 - 147
Drug resistance is a serious impediment to the treatment of cancer. The use of anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies in... 
miRNA | Therapy resistance | Anti-EGFR therapy | Epidermal growth factor receptor | Prognostic marker | CIRCULATING MICRORNAS | 1ST-LINE TREATMENT | TARGETING KRAS | DOWN-REGULATION | WILD-TYPE KRAS | DEPENDENT CELLULAR CYTOTOXICITY | PHASE-III TRIAL | MESSENGER-RNAS | ONCOLOGY | RAS MUTATIONS | MICRORNA EXPRESSION
Journal Article
Molecular Oncology, ISSN 1574-7891, 09/2014, Volume 8, Issue 6, pp. 1084 - 1094
Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies used as therapies for metastatic colorectal cancer... 
Acquired resistance | RAS | Panitumumab | Colorectal cancer | Cetuximab | Anti-EGFR therapy | MET
Journal Article
Journal Article
by Zhai, ZH and Yu, XH and Yang, B and Zhang, YJ and Zhang, L and Li, XL and Sun, HZ
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, ISSN 1084-9521, 04/2017, Volume 64, pp. 107 - 115
Precision medicine is becoming considerably critical in colorectal cancer therapy. Particularly for targeted therapies, the response to anti-EGFR therapy... 
EGFR MONOCLONAL-ANTIBODIES | PREDICTIVE BIOMARKER | INHIBITOR CETUXIMAB | Colorectal cancer | ACQUIRED-RESISTANCE | DEVELOPMENTAL BIOLOGY | Drug resistance | TUMOR HETEROGENEITY | CELL BIOLOGY | Heterogeneity | GROWTH-FACTOR RECEPTOR | Anti-EGFR therapies | CETUXIMAB PLUS IRINOTECAN | GENE COPY NUMBER | KRAS P.G13D MUTATION | EPIGENETIC ALTERATIONS
Journal Article
STEM CELLS Translational Medicine, ISSN 2157-6564, 04/2016, Volume 5, Issue 4, pp. 511 - 523
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 03/2016, Volume 46, Issue 3, pp. 228 - 233
Journal Article